Chelsie Derman

FDA clears BrainsWay's Deep TMS for adolescents aged 15-21 years with major depressive disorder (MDD), expanding its use.

This month in review spotlights the top psychiatry news from October 2025, featuring FDA's approval of UZEDY for bipolar I disorder.

A preview of 5 slated expert interviews and 5 late-breaking clinical trials to watch out for at ACAAI 2025.

This month in review spotlights 6 top allergy stories, from falling peanut allergy rates to intranasal steroid cream easing post-surgical rhinosinusitis.

Study finds non-celiac gluten or wheat sensitivity is more common in women and linked to IBS, anxiety, and depression.

A study found that combining the eosinophil-to-lymphocyte ratio with CT-based sinus scores predicts smell recovery after CRSwNP surgery.

A real-world study found that using baked goods with sesame paste was safer than raw sesame seeds for oral immunotherapy.

A study finds older adults with depression and comorbid anxiety show less improvement after accelerated theta burst stimulation.

Right transcutaneous auricular VNS (taVNS) acutely increases food liking in patients with MDD, especially those with high anhedonia, a study found.

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

A study found no major differences in overall cancer risk among adalimumab, secukinumab, and ustekinumab for psoriasis.

Investigators estimate that replacing individually prescribed school-based devices with spare adrenaline autoinjectors could improve access for students.

Adults given an initial 0.5 mg intramuscular epinephrine dose were less likely to need further intervention than those receiving 0.3 mg, a study found.

In a recent study, a 30 mg maintenance dose significantly increased reaction thresholds and improved immune markers in children with peanut allergy.

A new study finds that rates of peanut and other IgE-mediated food allergies declined following the 2015 and 2017 early peanut introduction guidelines.

The study showed that infants consuming blueberries had lower IL-13, higher IL-10, and improved allergy symptom trajectories compared with placebo.

Study finds repetitive transcranial magnetic stimulation brings clinically meaningful improvements in quality of life for adults with MDD through 12 weeks.

Post-hoc analysis of a phase 3 trial reveals significant improvements in patients with MDD experiencing tachyphylaxis.

A new study found that adjunct omalizumab helped most patients safely continue honeybee venom immunotherapy after prior severe allergic reactions.

A study found magnetic seizure therapy matched ECT’s antidepressant efficacy while offering better cognitive preservation and fewer adverse events.

A 5-year follow-up showed 76% of delabeled children reused the previously avoided antibiotic without significant adverse reactions.

A phase 1b/2a study showed CM326 significantly improved nasal polyp scores; baseline plasma TSLP levels ≥ 330 fg/mL may predict treatment response.

New research links soft drink consumption to depression, revealing gut microbiota changes as a potential mediator, particularly in women.

Study finds heart rate deceleration within 45 seconds of iTBS may serve as a biomarker for improved depression outcomes, regardless of stimulation site.

A new digital therapeutic, CT-155, shows promise in reducing negative symptoms of schizophrenia.

Roche’s Elecsys pTau181 blood test helps primary care clinicians rule out Alzheimer’s amyloid pathology in patients with cognitive symptoms.

Oticara’s intranasal steroid cream meets primary endpoints in phase 2 trial, providing rapid, durable symptom relief for post-surgical chronic rhinosinusitis.

A 9-year real-world study found allergen immunotherapy reduced medication use and asthma flare-ups, showing lasting control of allergic rhinitis.

New research links early baby formula feeding to increased risks of peanut and multiple food allergies, highlighting the importance of colostrum.

FDA approves UZEDY, a long-acting risperidone injection, for adults with bipolar I disorder.